标签归档：pd

PD0325901-O-C2-dioxolane

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

PD0325901-O-C2-dioxolane 

PD0325901-O-C2-dioxolane 含有 MEK 抑制剂 PD0325901 主要部分。PD0325901-O-C2-dioxolane 和 VHL 或 CRBN E3 连接酶的配体可用于 MEK1/2 降解剂的合成。

PD0325901-O-C2-dioxolane

PD0325901-O-C2-dioxolane Chemical Structure

CAS No. : 2581116-22-3

规格 价格 是否有货
5 mg ￥2200 询问价格 & 货期
10 mg ￥3500 询问价格 & 货期
25 mg ￥7000 询问价格 & 货期
50 mg ￥11500 询问价格 & 货期

* Please select Quantity before adding items.

生物活性

PD0325901-O-C2-dioxolane has main portion of MEK inhibitor PD0325901. PD0325901-O-C2-dioxolane and a ligand of VHL or CRBN E3 ligase can be used in the synthesis of MEK1/2 degrader[1].

IC50 & Target[1]

MEK1

 

MEK2

 

体外研究
(In Vitro)

PD0325901 is a non-ATP competitive MEK inhibitor, potently inhibits ERK signaling and proliferation of tumor cells[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

508.23

Formula

C18H16F3IN2O4
CAS 号

2581116-22-3
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Wei J, et al. Discovery of a First-in-Class Mitogen-Activated Protein Kinase Kinase 1/2 Degrader. J Med Chem. 2019;62(23):10897-10911.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

PD0325901-O-C2-dioxolane

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

PD0325901-O-C2-dioxolane 

PD0325901-O-C2-dioxolane 含有 MEK 抑制剂 PD0325901 主要部分。PD0325901-O-C2-dioxolane 和 VHL 或 CRBN E3 连接酶的配体可用于 MEK1/2 降解剂的合成。

PD0325901-O-C2-dioxolane

PD0325901-O-C2-dioxolane Chemical Structure

CAS No. : 2581116-22-3

规格 价格 是否有货
5 mg ￥2200 询问价格 & 货期
10 mg ￥3500 询问价格 & 货期
25 mg ￥7000 询问价格 & 货期
50 mg ￥11500 询问价格 & 货期

* Please select Quantity before adding items.

生物活性

PD0325901-O-C2-dioxolane has main portion of MEK inhibitor PD0325901. PD0325901-O-C2-dioxolane and a ligand of VHL or CRBN E3 ligase can be used in the synthesis of MEK1/2 degrader[1].

IC50 & Target[1]

MEK1

 

MEK2

 

体外研究
(In Vitro)

PD0325901 is a non-ATP competitive MEK inhibitor, potently inhibits ERK signaling and proliferation of tumor cells[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

508.23

Formula

C18H16F3IN2O4
CAS 号

2581116-22-3
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Wei J, et al. Discovery of a First-in-Class Mitogen-Activated Protein Kinase Kinase 1/2 Degrader. J Med Chem. 2019;62(23):10897-10911.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

PD0325901-O-C2-dioxolane

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

PD0325901-O-C2-dioxolane 

PD0325901-O-C2-dioxolane 含有 MEK 抑制剂 PD0325901 主要部分。PD0325901-O-C2-dioxolane 和 VHL 或 CRBN E3 连接酶的配体可用于 MEK1/2 降解剂的合成。

PD0325901-O-C2-dioxolane

PD0325901-O-C2-dioxolane Chemical Structure

CAS No. : 2581116-22-3

规格 价格 是否有货
5 mg ￥2200 询问价格 & 货期
10 mg ￥3500 询问价格 & 货期
25 mg ￥7000 询问价格 & 货期
50 mg ￥11500 询问价格 & 货期

* Please select Quantity before adding items.

生物活性

PD0325901-O-C2-dioxolane has main portion of MEK inhibitor PD0325901. PD0325901-O-C2-dioxolane and a ligand of VHL or CRBN E3 ligase can be used in the synthesis of MEK1/2 degrader[1].

IC50 & Target[1]

MEK1

 

MEK2

 

体外研究
(In Vitro)

PD0325901 is a non-ATP competitive MEK inhibitor, potently inhibits ERK signaling and proliferation of tumor cells[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

508.23

Formula

C18H16F3IN2O4
CAS 号

2581116-22-3
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Wei J, et al. Discovery of a First-in-Class Mitogen-Activated Protein Kinase Kinase 1/2 Degrader. J Med Chem. 2019;62(23):10897-10911.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

PD0166285 dihydrochloride

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

PD0166285 dihydrochloride 

PD0166285 dihydrochloride是 P-gp 的一个底物，是 WEE1 抑制剂，也可微弱抑制 Myt1，IC50 值分别为 24 和 72 nM。PD0166285 dihydrochloride 对 Chk1 的 IC50 值为3.433 μM。

PD0166285 dihydrochloride

PD0166285 dihydrochloride Chemical Structure

CAS No. : 212391-63-4

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

PD0166285 dihydrochloride 的其他形式现货产品:

PD0166285

生物活性

PD0166285 dihydrochloride, a substrate of P-gp, is a WEE1 inhibitor and a weak Myt1 inhibitor with IC50 values of 24 and 72 nM, respectively. PD0166285 dihydrochloride exhibits an IC50 of 3.433 μM for Chk1[1].

IC50 & Target

IC50: 24 nM (WEE1), 72 nM (Myt1), 3.433 μM (Chk1)[1].
体外研究
(In Vitro)

PD0166285 (0.5 μM) dramatically inhibits irradiation-induced Cdc2 phosphorylation at the Tyr-15 and Thr-14 in seven of seven cancer cell lines[1].
PD0166285 sensitizes radiation-induced cell killing in p53 mutant HT29 cells and in the E6-transfected, p53-null ovarian cancer cell line PA-1 but to a lesser extent in p53 wild-type PA-1 cells. PD0166285 abrogates irradiation-induced G2 arrest and significantly increases mitotic cell populations[1].
PD0166285 acts as a radiosensitizer to sensitize cells to radiation-induced cell death with a sensitivity enhancement ratio of 1.23[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line: Human and mouse cancer cell lines (HCT116, HT29, DLD-1, HCT8, H460, HeLa, C 26).
Concentration: 0.5 μM.
Incubation Time: 4 h.
Result: Inhibited Cdc2Y15 and CdcT14 phosphorylation.

体内研究
(In Vivo)
Animal Model: Wild-type, Abcg2-/-, Abcb1a/b-/- and Abcb1a/b;Abcg2-/- FVB mice[2].
Dosage: 5 mg/kg.
Administration: IV.
Result: Cmax is about 400 ng/mL.
P-gp, but not BCRP, limited the brain penetration of PD0166285.

分子量

585.35

Formula

C26H29Cl4N5O2
CAS 号

212391-63-4
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Wang Y, et al. Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator. Cancer Res. 2001 Nov 15;61(22):8211-7.

    [2]. Mark C de Gooijer, et al. ATP-binding cassette transporters limit the brain penetration of Wee1 inhibitors. Invest New Drugs. 2018 Jun;36(3):380-387.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

PD0166285 dihydrochloride

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

PD0166285 dihydrochloride 

PD0166285 dihydrochloride是 P-gp 的一个底物，是 WEE1 抑制剂，也可微弱抑制 Myt1，IC50 值分别为 24 和 72 nM。PD0166285 dihydrochloride 对 Chk1 的 IC50 值为3.433 μM。

PD0166285 dihydrochloride

PD0166285 dihydrochloride Chemical Structure

CAS No. : 212391-63-4

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

PD0166285 dihydrochloride 的其他形式现货产品:

PD0166285

生物活性

PD0166285 dihydrochloride, a substrate of P-gp, is a WEE1 inhibitor and a weak Myt1 inhibitor with IC50 values of 24 and 72 nM, respectively. PD0166285 dihydrochloride exhibits an IC50 of 3.433 μM for Chk1[1].

IC50 & Target

IC50: 24 nM (WEE1), 72 nM (Myt1), 3.433 μM (Chk1)[1].
体外研究
(In Vitro)

PD0166285 (0.5 μM) dramatically inhibits irradiation-induced Cdc2 phosphorylation at the Tyr-15 and Thr-14 in seven of seven cancer cell lines[1].
PD0166285 sensitizes radiation-induced cell killing in p53 mutant HT29 cells and in the E6-transfected, p53-null ovarian cancer cell line PA-1 but to a lesser extent in p53 wild-type PA-1 cells. PD0166285 abrogates irradiation-induced G2 arrest and significantly increases mitotic cell populations[1].
PD0166285 acts as a radiosensitizer to sensitize cells to radiation-induced cell death with a sensitivity enhancement ratio of 1.23[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line: Human and mouse cancer cell lines (HCT116, HT29, DLD-1, HCT8, H460, HeLa, C 26).
Concentration: 0.5 μM.
Incubation Time: 4 h.
Result: Inhibited Cdc2Y15 and CdcT14 phosphorylation.

体内研究
(In Vivo)
Animal Model: Wild-type, Abcg2-/-, Abcb1a/b-/- and Abcb1a/b;Abcg2-/- FVB mice[2].
Dosage: 5 mg/kg.
Administration: IV.
Result: Cmax is about 400 ng/mL.
P-gp, but not BCRP, limited the brain penetration of PD0166285.

分子量

585.35

Formula

C26H29Cl4N5O2
CAS 号

212391-63-4
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Wang Y, et al. Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator. Cancer Res. 2001 Nov 15;61(22):8211-7.

    [2]. Mark C de Gooijer, et al. ATP-binding cassette transporters limit the brain penetration of Wee1 inhibitors. Invest New Drugs. 2018 Jun;36(3):380-387.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

PD0166285 dihydrochloride

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

PD0166285 dihydrochloride 

PD0166285 dihydrochloride是 P-gp 的一个底物，是 WEE1 抑制剂，也可微弱抑制 Myt1，IC50 值分别为 24 和 72 nM。PD0166285 dihydrochloride 对 Chk1 的 IC50 值为3.433 μM。

PD0166285 dihydrochloride

PD0166285 dihydrochloride Chemical Structure

CAS No. : 212391-63-4

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

PD0166285 dihydrochloride 的其他形式现货产品:

PD0166285

生物活性

PD0166285 dihydrochloride, a substrate of P-gp, is a WEE1 inhibitor and a weak Myt1 inhibitor with IC50 values of 24 and 72 nM, respectively. PD0166285 dihydrochloride exhibits an IC50 of 3.433 μM for Chk1[1].

IC50 & Target

IC50: 24 nM (WEE1), 72 nM (Myt1), 3.433 μM (Chk1)[1].
体外研究
(In Vitro)

PD0166285 (0.5 μM) dramatically inhibits irradiation-induced Cdc2 phosphorylation at the Tyr-15 and Thr-14 in seven of seven cancer cell lines[1].
PD0166285 sensitizes radiation-induced cell killing in p53 mutant HT29 cells and in the E6-transfected, p53-null ovarian cancer cell line PA-1 but to a lesser extent in p53 wild-type PA-1 cells. PD0166285 abrogates irradiation-induced G2 arrest and significantly increases mitotic cell populations[1].
PD0166285 acts as a radiosensitizer to sensitize cells to radiation-induced cell death with a sensitivity enhancement ratio of 1.23[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line: Human and mouse cancer cell lines (HCT116, HT29, DLD-1, HCT8, H460, HeLa, C 26).
Concentration: 0.5 μM.
Incubation Time: 4 h.
Result: Inhibited Cdc2Y15 and CdcT14 phosphorylation.

体内研究
(In Vivo)
Animal Model: Wild-type, Abcg2-/-, Abcb1a/b-/- and Abcb1a/b;Abcg2-/- FVB mice[2].
Dosage: 5 mg/kg.
Administration: IV.
Result: Cmax is about 400 ng/mL.
P-gp, but not BCRP, limited the brain penetration of PD0166285.

分子量

585.35

Formula

C26H29Cl4N5O2
CAS 号

212391-63-4
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Wang Y, et al. Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator. Cancer Res. 2001 Nov 15;61(22):8211-7.

    [2]. Mark C de Gooijer, et al. ATP-binding cassette transporters limit the brain penetration of Wee1 inhibitors. Invest New Drugs. 2018 Jun;36(3):380-387.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Human PD-L1 inhibitor II

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Human PD-L1 inhibitor II 

Human PD-L1 inhibitor II 是有效 PD-L1 抑制剂，具有抗癌活性。

Human PD-L1 inhibitor II

Human PD-L1 inhibitor II Chemical Structure

CAS No. : 2135542-85-5

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Human PD-L1 inhibitor II is a potent PD-L1 inhibitor with anti-cancer activity[1].

分子量

2219.45

Formula

C103H151N25O30
CAS 号

2135542-85-5
Sequence

Phe-Asn-Trp-Asp-Tyr-Ser-Leu-Glu-Glu-Leu-Arg-Glu-Lys-Ala-Lys-Tyr-Lys
Sequence Shortening

FNWDYSLEELREKAKYK
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
Solvent & Solubility
In Vitro: 

H2O

Peptide Solubility and Storage Guidelines:

1.  Calculate the length of the peptide.

2.  Calculate the overall charge of the entire peptide according to the following table:

  Contents Assign value
Acidic amino acid Asp (D), Glu (E), and the C-terminal -COOH. -1
Basic amino acid Arg (R), Lys (K), His (H), and the N-terminal -NH2 +1
Neutral amino acid Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q) 0

3.  Recommended solution:

Overall charge of peptide Details
Negative (<0) 1.  Try to dissolve the peptide in water first.
2.  If water fails, add NH4OH (<50 μL).
3.  If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide.
Positive (>0) 1.  Try to dissolve the peptide in water first.
2.  If water fails, try dissolving the peptide in a 10%-30% acetic acid solution.
3.  If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO.
Zero (=0) 1.  Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first.
2.  For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration.
参考文献

  • [1]. Honglin Li, et al. Pd-1 targeting polypeptide and use thereof. WO2017162208A1

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Human PD-L1 inhibitor II

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Human PD-L1 inhibitor II 

Human PD-L1 inhibitor II 是有效 PD-L1 抑制剂，具有抗癌活性。

Human PD-L1 inhibitor II

Human PD-L1 inhibitor II Chemical Structure

CAS No. : 2135542-85-5

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Human PD-L1 inhibitor II is a potent PD-L1 inhibitor with anti-cancer activity[1].

分子量

2219.45

Formula

C103H151N25O30
CAS 号

2135542-85-5
Sequence

Phe-Asn-Trp-Asp-Tyr-Ser-Leu-Glu-Glu-Leu-Arg-Glu-Lys-Ala-Lys-Tyr-Lys
Sequence Shortening

FNWDYSLEELREKAKYK
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
Solvent & Solubility
In Vitro: 

H2O

Peptide Solubility and Storage Guidelines:

1.  Calculate the length of the peptide.

2.  Calculate the overall charge of the entire peptide according to the following table:

  Contents Assign value
Acidic amino acid Asp (D), Glu (E), and the C-terminal -COOH. -1
Basic amino acid Arg (R), Lys (K), His (H), and the N-terminal -NH2 +1
Neutral amino acid Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q) 0

3.  Recommended solution:

Overall charge of peptide Details
Negative (<0) 1.  Try to dissolve the peptide in water first.
2.  If water fails, add NH4OH (<50 μL).
3.  If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide.
Positive (>0) 1.  Try to dissolve the peptide in water first.
2.  If water fails, try dissolving the peptide in a 10%-30% acetic acid solution.
3.  If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO.
Zero (=0) 1.  Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first.
2.  For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration.
参考文献

  • [1]. Honglin Li, et al. Pd-1 targeting polypeptide and use thereof. WO2017162208A1

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Human PD-L1 inhibitor II

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Human PD-L1 inhibitor II 

Human PD-L1 inhibitor II 是有效 PD-L1 抑制剂，具有抗癌活性。

Human PD-L1 inhibitor II

Human PD-L1 inhibitor II Chemical Structure

CAS No. : 2135542-85-5

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Human PD-L1 inhibitor II is a potent PD-L1 inhibitor with anti-cancer activity[1].

分子量

2219.45

Formula

C103H151N25O30
CAS 号

2135542-85-5
Sequence

Phe-Asn-Trp-Asp-Tyr-Ser-Leu-Glu-Glu-Leu-Arg-Glu-Lys-Ala-Lys-Tyr-Lys
Sequence Shortening

FNWDYSLEELREKAKYK
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
Solvent & Solubility
In Vitro: 

H2O

Peptide Solubility and Storage Guidelines:

1.  Calculate the length of the peptide.

2.  Calculate the overall charge of the entire peptide according to the following table:

  Contents Assign value
Acidic amino acid Asp (D), Glu (E), and the C-terminal -COOH. -1
Basic amino acid Arg (R), Lys (K), His (H), and the N-terminal -NH2 +1
Neutral amino acid Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q) 0

3.  Recommended solution:

Overall charge of peptide Details
Negative (<0) 1.  Try to dissolve the peptide in water first.
2.  If water fails, add NH4OH (<50 μL).
3.  If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide.
Positive (>0) 1.  Try to dissolve the peptide in water first.
2.  If water fails, try dissolving the peptide in a 10%-30% acetic acid solution.
3.  If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO.
Zero (=0) 1.  Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first.
2.  For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration.
参考文献

  • [1]. Honglin Li, et al. Pd-1 targeting polypeptide and use thereof. WO2017162208A1

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Human PD-L1 inhibitor I

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Human PD-L1 inhibitor I 

Human PD-L1 inhibitor I 是一种 hPD-1 肽配体，KD 值为 3.39 μM。Human PD-L1 inhibitor I 可能可以干扰 hPD-L1 与 hPD-1 的结合。

Human PD-L1 inhibitor I

Human PD-L1 inhibitor I Chemical Structure

CAS No. : 2135542-86-6

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Human PD-L1 inhibitor I is a hPD-1 peptide ligand, with a KD of 3.39 μM. Human PD-L1 inhibitor I may disturb the binding of hPD-L1 to hPD-1[1].

分子量

2350.58

Formula

C110H152N26O32
CAS 号

2135542-86-6
Sequence

Phe-Asn-Trp-Asp-Tyr-Ser-Trp-Lys-Ser-Glu-Arg-Leu-Lys-Glu-Ala-Tyr-Asp-Leu
Sequence Shortening

FNWDYSWKSERLKEAYDL
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Tianyu Wang, et al. Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway. J Med Chem. 2019 Feb 28;62(4):1715-1730.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Human PD-L1 inhibitor I

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Human PD-L1 inhibitor I 

Human PD-L1 inhibitor I 是一种 hPD-1 肽配体，KD 值为 3.39 μM。Human PD-L1 inhibitor I 可能可以干扰 hPD-L1 与 hPD-1 的结合。

Human PD-L1 inhibitor I

Human PD-L1 inhibitor I Chemical Structure

CAS No. : 2135542-86-6

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Human PD-L1 inhibitor I is a hPD-1 peptide ligand, with a KD of 3.39 μM. Human PD-L1 inhibitor I may disturb the binding of hPD-L1 to hPD-1[1].

分子量

2350.58

Formula

C110H152N26O32
CAS 号

2135542-86-6
Sequence

Phe-Asn-Trp-Asp-Tyr-Ser-Trp-Lys-Ser-Glu-Arg-Leu-Lys-Glu-Ala-Tyr-Asp-Leu
Sequence Shortening

FNWDYSWKSERLKEAYDL
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Tianyu Wang, et al. Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway. J Med Chem. 2019 Feb 28;62(4):1715-1730.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Human PD-L1 inhibitor I

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Human PD-L1 inhibitor I 

Human PD-L1 inhibitor I 是一种 hPD-1 肽配体，KD 值为 3.39 μM。Human PD-L1 inhibitor I 可能可以干扰 hPD-L1 与 hPD-1 的结合。

Human PD-L1 inhibitor I

Human PD-L1 inhibitor I Chemical Structure

CAS No. : 2135542-86-6

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Human PD-L1 inhibitor I is a hPD-1 peptide ligand, with a KD of 3.39 μM. Human PD-L1 inhibitor I may disturb the binding of hPD-L1 to hPD-1[1].

分子量

2350.58

Formula

C110H152N26O32
CAS 号

2135542-86-6
Sequence

Phe-Asn-Trp-Asp-Tyr-Ser-Trp-Lys-Ser-Glu-Arg-Leu-Lys-Glu-Ala-Tyr-Asp-Leu
Sequence Shortening

FNWDYSWKSERLKEAYDL
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Tianyu Wang, et al. Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway. J Med Chem. 2019 Feb 28;62(4):1715-1730.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Human PD-L1 inhibitor III

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Human PD-L1 inhibitor III 

Human PD-L1 inhibitor III 是人的 PD-L1 的抑制剂。

Human PD-L1 inhibitor III

Human PD-L1 inhibitor III Chemical Structure

CAS No. : 2135542-84-4

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Human PD-L1 inhibitor III is a human PD-L1 inhibitor.

分子量

2223.70

Formula

C97H155N29O29S1
CAS 号

2135542-84-4
Sequence Shortening

TEKDYRHGNIRMKLAYDL
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
Solvent & Solubility
In Vitro: 

H2O

Peptide Solubility and Storage Guidelines:

1.  Calculate the length of the peptide.

2.  Calculate the overall charge of the entire peptide according to the following table:

  Contents Assign value
Acidic amino acid Asp (D), Glu (E), and the C-terminal -COOH. -1
Basic amino acid Arg (R), Lys (K), His (H), and the N-terminal -NH2 +1
Neutral amino acid Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q) 0

3.  Recommended solution:

Overall charge of peptide Details
Negative (<0) 1.  Try to dissolve the peptide in water first.
2.  If water fails, add NH4OH (<50 μL).
3.  If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide.
Positive (>0) 1.  Try to dissolve the peptide in water first.
2.  If water fails, try dissolving the peptide in a 10%-30% acetic acid solution.
3.  If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO.
Zero (=0) 1.  Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first.
2.  For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

英国Prima PD500-TP分散匀浆机（1-13L）

发表于由

【简单介绍】

品牌 其他品牌

英国Prima PD500-TP分散匀浆机（1-13L）一款专为生物制药、基因研究、组织破碎、细胞浆化、病理分析、乳品均质、聚合反应等实验与生产领域而研发的全新产品；具有操作方便、性能优越、噪音低、可无极变速控制且适合长时间运转等特点。
英国进口！

！

【详细说明】

英国Prima PD500-TP分散匀浆机（1-13L）

产品简述：

  英国Prima PD500-TP分散匀浆机（1-13L）一款专为生物制药、基因研究、组织破碎、细胞浆化、病理分析、乳品均质、聚合反应等实验与生产领域而研发的全新产品；具有操作方便、性能优越、噪音低、可无极变速控制且适合长时间运转等特点。所有的分散刀头都是可更换的且方便清洗灭菌。可选的多种分散刀头满足了其处理量从1-13000 ml (H2O)，宽广的转速范围(300-28000 rpm)及数字显示转速功能确保了电机能即时有效补偿因负载变化和电源电压波动而引起的转速变化。

产品特点：

  1. 高强度塑料机壳，双重绝缘，保证使用安全
  2. 数字显示转速，转速可在300-28000rpm间任意调节            
  3. 分散头采用优势不锈钢材质特制，并有电烤漆涂层，可重复使用
  4. 分散头采用快速连接方式、便于拆卸更换及高温高压消毒
  5. 运转平稳、噪音低，不会加速变速
  6. 可配备五种不同的分散头，满足您不同处理量
  7. 电子过载保护

技术参数：

型号/订货号

PD500

转速 rpm

300-28000

处理粘度 cp

8000

处理量（H2O） ml          

1-13000

转速显示           

LED

功率  W

500

重量  kg

10

外形尺寸 mm

350x250x750

电源 V

220-240（50-60HZ）

防护等级

IP20

工作架底座

标配

配套刀头

型号

TP12

TP18

TP24

TP30

TP36

分散头长度（mm）

110

210

230

230

230

分散头直径（mm）

12

18

24

30

36

线速度（m/s）

10

15

20

25

28

工作体积（ml）

1-1000

50-1500

50-5000

50-8000

100-13000

Human PD-L1 inhibitor III

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Human PD-L1 inhibitor III 

Human PD-L1 inhibitor III 是人的 PD-L1 的抑制剂。

Human PD-L1 inhibitor III

Human PD-L1 inhibitor III Chemical Structure

CAS No. : 2135542-84-4

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Human PD-L1 inhibitor III is a human PD-L1 inhibitor.

分子量

2223.70

Formula

C97H155N29O29S1
CAS 号

2135542-84-4
Sequence Shortening

TEKDYRHGNIRMKLAYDL
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
Solvent & Solubility
In Vitro: 

H2O

Peptide Solubility and Storage Guidelines:

1.  Calculate the length of the peptide.

2.  Calculate the overall charge of the entire peptide according to the following table:

  Contents Assign value
Acidic amino acid Asp (D), Glu (E), and the C-terminal -COOH. -1
Basic amino acid Arg (R), Lys (K), His (H), and the N-terminal -NH2 +1
Neutral amino acid Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q) 0

3.  Recommended solution:

Overall charge of peptide Details
Negative (<0) 1.  Try to dissolve the peptide in water first.
2.  If water fails, add NH4OH (<50 μL).
3.  If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide.
Positive (>0) 1.  Try to dissolve the peptide in water first.
2.  If water fails, try dissolving the peptide in a 10%-30% acetic acid solution.
3.  If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO.
Zero (=0) 1.  Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first.
2.  For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

英国Prima PD300-TE高剪切匀浆机（1-12L）

发表于由

【简单介绍】

品牌 其他品牌

英国Prima PD300-TE高剪切匀浆机（1-12L）是一款专为生物制药、基因研究、组织破碎、细胞浆化、病理分析、乳品均质、聚合反应等实验与生产领域而研发的全新产品；具有操作方便、性能优越、噪音低、可无极变速控制且适合长时间运转等特点。

英国进口！

！

【详细说明】

英国Prima PD300-TE高剪切匀浆机（1-12L）

产品简述：

  英国Prima PD300-TE高剪切匀浆机（1-12L）是一款专为生物制药、基因研究、组织破碎、细胞浆化、病理分析、乳品均质、聚合反应等实验与生产领域而研发的全新产品；具有操作方便、性能优越、噪音低、可无极变速控制且适合长时间运转等特点。可选的多种分散刀头满足了其处理量从1-15000 ml (H2O)，宽广的转速范围(300-15000 rpm)及数字显示转速功能确保了电机能即时有效补偿因负载变化和电源电压波动而引起的转速变化。

产品特点：

  1. 高强度塑料机壳，双重绝缘，保证使用安全。
  2. 数字显示转速，转速可在300-15000rpm间任意调节。            
  3. 运转平稳、噪音低，不会加速变速。
  4. 转子采用优势不锈钢材质特制，并有电烤漆涂层，可重复使用。
  5. 可配备三种不同的转子，满足您不同工艺要求。
  6. 所有的分散刀头都是可更换的且方便清洗灭菌。
  7. 轴套使用铜合金材质、便于拆卸更换及高温高压消毒。
  8. 电子过载保护。

技术参数：

型号/订货号

PD300

转速 rpm

300-15000

大处理粘度 cp

5000

处理量（H2O） ml          

1-12000

转速显示           

LED

功率  W

300

重量 kg

10

外形尺寸 mm

350x250x750

电源 V

220-240（50-60HZ）

防护等级

IP20

工作架底座

标配

Human PD-L1 inhibitor III

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Human PD-L1 inhibitor III 

Human PD-L1 inhibitor III 是人的 PD-L1 的抑制剂。

Human PD-L1 inhibitor III

Human PD-L1 inhibitor III Chemical Structure

CAS No. : 2135542-84-4

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Human PD-L1 inhibitor III is a human PD-L1 inhibitor.

分子量

2223.70

Formula

C97H155N29O29S1
CAS 号

2135542-84-4
Sequence Shortening

TEKDYRHGNIRMKLAYDL
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
Solvent & Solubility
In Vitro: 

H2O

Peptide Solubility and Storage Guidelines:

1.  Calculate the length of the peptide.

2.  Calculate the overall charge of the entire peptide according to the following table:

  Contents Assign value
Acidic amino acid Asp (D), Glu (E), and the C-terminal -COOH. -1
Basic amino acid Arg (R), Lys (K), His (H), and the N-terminal -NH2 +1
Neutral amino acid Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q) 0

3.  Recommended solution:

Overall charge of peptide Details
Negative (<0) 1.  Try to dissolve the peptide in water first.
2.  If water fails, add NH4OH (<50 μL).
3.  If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide.
Positive (>0) 1.  Try to dissolve the peptide in water first.
2.  If water fails, try dissolving the peptide in a 10%-30% acetic acid solution.
3.  If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO.
Zero (=0) 1.  Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first.
2.  For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Tislelizumab

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Tislelizumab 

Tislelizumab 是一种对 PD-1 受体具有高结合亲和力的单克隆抗体，可最大限度地减少 Fcγ 受体与巨噬细胞的结合，从而消除抗体依赖性吞噬作用，这是一种 T 细胞清除机制，可对抗 PD-1 治疗的潜在耐药性。Tislelizumab 可用于晚期鳞状非小细胞肺癌的研究。

Tislelizumab

Tislelizumab Chemical Structure

CAS No. : 1858168-59-8

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Tislelizumab, a monoclonal antibody with high binding affinity to the PD-1 receptor, minimizes Fcγ receptor binding on macrophages, thereby abrogating antibody-dependent phagocytosis, a mechanism of T cell clearance and potential resistance to anti-PD-1 therapy. Tislelizumab can be used for the research of advanced squamous non-small-cell lung cancer[1].

CAS 号

1858168-59-8
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Jie Wang, et al. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021 May 1;7(5):709-717.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Spartalizumab(Synonyms: PDR001)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Spartalizumab (Synonyms: PDR001)

Spartalizumab (PDR001) 是一种人源化的免疫球蛋白 4 单克隆抗体，以亚纳摩尔活性结合 PD-1，并阻断与 PD-L1 和 PD-L2 的相互作用。Spartalizumab 可用于甲状腺未分化癌 (ATC) 的研究。

Spartalizumab(Synonyms: PDR001)

Spartalizumab Chemical Structure

CAS No. : 1935694-88-4

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Spartalizumab (PDR001) is a humanized immunoglobulin 4 monoclonal antibody that binds PD-1 with subnanomolar activity and blocks interaction with PD-L1 and PD-L2. Spartalizumab can be used for the research of anaplastic thyroid carcinoma (ATC)[1].

CAS 号

1935694-88-4
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Jaume Capdevila, et al. PD-1 Blockade in Anaplastic Thyroid Carcinoma. J Clin Oncol. 2020 Aug 10;38(23):2620-2627.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Sintilimab(Synonyms: IBI308)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Sintilimab (Synonyms: IBI308)

Sintilimab (IBI308) 是一种人源化的 IgG4 单克隆抗体，可与 PD-1 结合，从而阻断 PD-1 与其配体 (PD-L1 和 PL-L2) 的相互作用，从而有助于恢复内源性抗肿瘤 T 细胞反应。Sintilimab 可用于经典霍奇金淋巴瘤、非小细胞肺癌和食管癌的研究。

Sintilimab(Synonyms: IBI308)

Sintilimab Chemical Structure

CAS No. : 2072873-06-2

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Sintilimab (IBI308) is a fully human IgG4 monoclonal antibody that binds to PD-1, thereby blocking the interaction of PD-1 with its ligands (PD-L1 and PL-L2) and consequently helping to restore the endogenous antitumour T-cell response. Sintilimab can be used for the research of classical Hodgkin’s lymphoma, non-small cell lung cancer and oesophageal cancer[1].

CAS 号

2072873-06-2
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Sheridan M Hoy. Sintilimab: First Global Approval Drugs. 2019 Feb;79(3):341-346.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务